{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:26:47Z","timestamp":1792031207166,"version":"4.4.0"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell systemic immunotherapy has revolutionized how clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar mechanism of action, CAR T-cell-based therapy has enlarged the spectrum of neurological toxicities. CAR T-cell-associated neurotoxicity\u2014initially defined as CAR T-cell-related encephalopathy syndrome (CRES) and currently coined within the acronym ICANS (immune effector cell-associated neurotoxicity syndrome)\u2014is perhaps the most concerning toxicity of CAR T-cell therapy. Importantly, hematologic malignancies (especially lymphoid malignancies) may originate in or spread to the central nervous system (CNS) in the form of parenchymal and\/or meningeal disease. Due to the emergence of deadly and neurological adverse events, such as fatal brain edema in some patients included in early CAR T-cell trials, safety concerns for those with CNS primary or secondary infiltration arose and contributed to the routine exclusion of individuals with pre-existing or active CNS involvement from pivotal trials. However, based primarily on the lack of evidence, it remains unknown whether CNS involvement increases the risk and\/or severity of CAR T-cell-related neurotoxicity. Given the limited treatment options available for patients once they relapse with CNS involvement, it is of high interest to explore the role of novel clinical strategies including CAR T cells to treat leukemias\/lymphomas and myeloma with CNS involvement. The purpose of this review was to summarize currently available neurological safety data of CAR T-cell-based immunotherapy from the clinical trials and real-world experiences in adult patients with CNS disease due to lymphoma, leukemia, or myeloma. Increasing evidence supports that CNS involvement in hematologic disease should no longer be considered <jats:italic>per se<\/jats:italic> as an absolute contraindication to CAR T-cell-based therapy. While the incidence may be high, severity does not appear to be impacted significantly by pre-existing CNS status. Close monitoring by trained neurologists is recommended.<\/jats:p>","DOI":"10.3389\/fneur.2023.1144414","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T05:43:05Z","timestamp":1680759785000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern?"],"prefix":"10.3389","volume":"14","author":[{"given":"Roser","family":"Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macarena","family":"Villagr\u00e1n-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","article-title":"Cancer-treatment-induced neurotoxicity\u2014focus on newer treatments","volume":"13","author":"Stone","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","unstructured":"Cancer Neurology in Clinical Practice\n            SchiffD\n            ArrillagaI\n            WenPY\n          ChamSpringer International Publishing2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"879608","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"936141","DOI":"10.3389\/fneur.2022.936141","article-title":"The role of neurologists in the era of cancer immunotherapy: focus on CAR T-cell therapy and immune checkpoint inhibitors","volume":"13","author":"Pensato","year":"2022","journal-title":"Front Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","article-title":"Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma","volume":"40","author":"Wang","year":"2022","journal-title":"JCO"},{"key":"B18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00415-021-10766-5","article-title":"Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity","volume":"269","author":"Pensato","year":"2022","journal-title":"J Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell\u2013associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"Neuro Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with b-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B21","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1007\/s00415-022-11117-8","article-title":"Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review","volume":"269","author":"Pensato","year":"2022","journal-title":"J Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jnen\/nly064","article-title":"Neuropathology of a case with fatal CAR T-cell-associated cerebral edema","volume":"77","author":"Torre","year":"2018","journal-title":"J Neuropathol Exp Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"B27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1576","DOI":"10.1002\/wsbm.1576","article-title":"Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment","volume":"14","author":"Gu","year":"2022","journal-title":"WIREs Mech Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1369\/00221554221079579","article-title":"Comprehensive BCMA expression profiling in adult normal human brain suggests a low risk of on-target neurotoxicity in BCMA-targeting multiple myeloma therapy","volume":"70","author":"Marella","year":"2022","journal-title":"J Histochem Cytochem"},{"key":"B33","doi-asserted-by":"publisher","first-page":"103453","DOI":"10.1016\/j.critrevonc.2021.103453","article-title":"Rethinking mechanisms of neurotoxicity with BCMA directed therapy","volume":"166","author":"Mohyuddin","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","article-title":"Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial","volume":"139","author":"Frigault","year":"2022","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/neuonc\/noac034","article-title":"Neurotoxicity following CD19\/CD28\u03b6 CAR T-cells in children and young adults with B-cell malignancies","volume":"24","author":"Shalabi","year":"2022","journal-title":"Neuro Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma","volume":"5","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"key":"B39","doi-asserted-by":"publisher","first-page":"100838","DOI":"10.1016\/j.tranon.2020.100838","article-title":"Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia","volume":"13","author":"Chen","year":"2020","journal-title":"Transl Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell\u2013based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"B43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11060-020-03547-z","article-title":"Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study","volume":"148","year":"2020","journal-title":"J Neurooncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3324\/haematol.2022.281457","article-title":"Prevention and management of secondary central nervous system lymphoma","volume":"108","author":"Bobillo","year":"2023","journal-title":"Haematol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"JCO"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.21037\/atm-20-3140","article-title":"A narrative review of central nervous system involvement in acute leukemias","volume":"9","author":"Deak","year":"2021","journal-title":"Ann Transl Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e2014075","DOI":"10.4084\/mjhid.2014.075","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis and therapy","volume":"6","author":"Del Principe","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jocn.2009.11.015","article-title":"Can leptomeningeal myelomatosis be predicted in patients with IgD multiple myeloma?","volume":"17","author":"Velasco","year":"2010","journal-title":"J Clin Neurosci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fonc.2019.01350","article-title":"CD19 and CD70 dual-target chimeric antigen receptor t-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma","volume":"9","author":"Tu","year":"2019","journal-title":"Front Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0838-y","article-title":"Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis","volume":"13","author":"Abbasi","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.mayocp.2019.09.006","article-title":"Axicabtagene ciloleucel chimeric antigen receptor T cell therapy in lymphoma with secondary central nervous system involvement","volume":"94","author":"Novo","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B56","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/10428194.2019.1695052","article-title":"What a headache! Double-hit lymphoma with CNS recurrence \u2013 Role of chimeric antigen receptor (CAR) T-cell therapy","volume":"61","author":"Rafelson","year":"2020","journal-title":"Leuk Lymph"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e27733","DOI":"10.1097\/MD.0000000000027733","article-title":"Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: a case report","volume":"100","author":"Yagi","year":"2021","journal-title":"Medicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"817969","DOI":"10.3389\/fonc.2022.817969","article-title":"Sequential CAR T-cell therapy After autologous stem cell transplantation for the treatment of relapsed\/refractory intravascular large B-cell lymphoma with central nervous system involvement: a case report","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/bloodadvances.2022008031","article-title":"CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse","volume":"7","author":"Vu","year":"2022","journal-title":"Blood Adv"},{"key":"B60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12015-020-10092-9","article-title":"Treatment of aggressive T cell lymphoblastic lymphoma\/leukemia using anti-CD5 CAR T cells","volume":"17","author":"Feng","year":"2021","journal-title":"Stem Cell Rev and Rep"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1038\/s41409-021-01471-y","article-title":"Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement","volume":"56","author":"Hu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.1016\/j.clml.2020.12.009","article-title":"Safety and efficacy of chimeric antigen receptor T-cell therapy in children with central nervous system leukemia","volume":"21","author":"Zhang","year":"2021","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B63","doi-asserted-by":"publisher","first-page":"854448","DOI":"10.3389\/fonc.2022.854448\/full","article-title":"Clinical outcomes of BCMA CAR-T cells in a multiple myeloma patient with central nervous system invasion","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/CJI.0000000000000391","article-title":"BCMA CAR-T therapy is safe and effective for refractory\/relapsed multiple myeloma with central nervous system involvement","volume":"45","author":"Wang","year":"2022","journal-title":"J Immunother"},{"key":"B65","doi-asserted-by":"publisher","first-page":"755584","DOI":"10.3389\/fonc.2021.755584","article-title":"Successful BCMA CAR-T therapy for multiple myeloma with central nervous system involvement manifesting as cauda equina syndrome\u2014a wandering road to remission","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"552429","DOI":"10.3389\/fimmu.2021.552429","article-title":"Case report: reversible neurotoxicity and a clinical response induced by BCMA-directed chimeric antigen receptor T cells against multiple myeloma with central nervous system involvement","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005292","article-title":"CAR T-cell therapy for secondary CNS DLBCL","author":"Ahmed","year":"2021","journal-title":"Blood Adv"},{"key":"B68","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1182\/blood.2021012932","article-title":"CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network","volume":"139","author":"Alcantara","year":"2022","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"10394","DOI":"10.1182\/blood-2022-166104","article-title":"Real-world results of CAR-T cell therapy for large B cell lymphoma with CNS involvement: a GLA\/DRST study","volume":"140","author":"Ayuk","year":"2022","journal-title":"Blood."},{"key":"B70","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood-2019-129097","article-title":"Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US lymphoma CAR T consortium","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.clml.2021.07.002","article-title":"Real-world experience of axicabtagene ciloleucel and tisagenlecleucel for relapsed or refractory aggressive B-cell lymphomas: a single-institution experience","volume":"21","author":"Ghafouri","year":"2021","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2022-165256","article-title":"A pilot study of axicabtagene ciloleucel (axi-cel) for the treatment of relapsed\/refractory primary and secondary central nervous system lymphoma (CNSL)","volume":"140","author":"Jacobson","year":"2022","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"key":"B75","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1212\/WNL.0000000000200608","article-title":"Toxicities and response rates of secondary CNS lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T cells","volume":"98","author":"Karschnia","year":"2022","journal-title":"Neurology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3389\/fonc.2020.01306","article-title":"CAR T-cell therapy is effective but not long-lasting in B-cell lymphoma of the brain","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1089\/hum.2021.249","article-title":"CD19 or CD20 CAR T cell therapy demonstrates durable antitumor efficacy in patients with central nervous system lymphoma","volume":"33","author":"Liu","year":"2022","journal-title":"Hum Gene Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1182\/bloodadvances.2021004557","article-title":"Sequential different B-cell antigen\u2013targeted CAR T-cell therapy for pediatric refractory\/relapsed Burkitt lymphoma","volume":"6","author":"Liu","year":"2022","journal-title":"Blood Adv"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"JCO"},{"key":"B81","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1182\/blood-2022-167784","article-title":"Efficacy of CAR-T cells in primary central nervous system lymphomas: the French Experience of the National LOC Network","volume":"140","author":"Sylvain","year":"2022","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00262-020-02829-9","article-title":"Toxicity and effectiveness of CD19 CAR T therapy in children with high-burden central nervous system refractory B-ALL","volume":"70","author":"Tan","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B84","doi-asserted-by":"publisher","first-page":"693200","DOI":"10.3389\/fimmu.2021.693200","article-title":"Efficacy and safety of axicabtagene ciloleucel and tisagenlecleucel administration in lymphoma patients with secondary CNS involvement: a systematic review","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2900310","article-title":"The autologous hematopoietic stem cells transplantation combination-based chimeric antigen receptor T-cell therapy improves outcomes of relapsed\/refractory central nervous system B-cell lymphoma. Kang Z, editor","volume":"2022","author":"Xue","year":"2022","journal-title":"J Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/CJI.0000000000000416","article-title":"Axicabtagene ciloleucel in patients ineligible for ZUMA-1 because of CNS involvement and\/or HIV: a multicenter experience","volume":"45","author":"Yuen","year":"2022","journal-title":"J Immunother"},{"key":"B87","doi-asserted-by":"publisher","first-page":"965224","DOI":"10.3389\/fimmu.2022.965224","article-title":"Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.56875\/2589-0646.1024","article-title":"Chimeric antigen receptor T-cell therapies in lymphoma patients with central nervous system involvement","volume":"15","author":"Yi","year":"2022","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clml.2022.09.008","article-title":"Chimeric antigen receptor T-cell (CAR T-cell) therapy for primary and secondary central nervous system lymphoma: a systematic review of literature","volume":"23","author":"Asghar","year":"2023","journal-title":"Clin Lymph Myeloma Leuk."},{"key":"B90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in PCNSL and SCNSL: a meta-analysis of 128 patients","volume":"7","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"B91","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1144414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T05:43:10Z","timestamp":1680759790000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1144414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":91,"alternative-id":["10.3389\/fneur.2023.1144414"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1144414","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"article-number":"1144414"}}